Metabolomic differences between exanthematous drug eruption and infectious mononucleosis.

Yanqiu Liu, Qizhen Guan, Liyuan Liu, Lina Ma, Xinsuo Duan, Jiaozi Che
Author Information
  1. Yanqiu Liu: Department of Dermatology and Venereology, The Affiliated Hospital of Chengde Medical University, Chengde, China. ORCID
  2. Qizhen Guan: Department of Dermatology and Venereology, The Affiliated Hospital of Chengde Medical University, Chengde, China.
  3. Liyuan Liu: Department of Dermatology and Venereology, The Affiliated Hospital of Chengde Medical University, Chengde, China.
  4. Lina Ma: Department of Dermatology and Venereology, The Affiliated Hospital of Chengde Medical University, Chengde, China.
  5. Xinsuo Duan: Department of Dermatology and Venereology, The Affiliated Hospital of Chengde Medical University, Chengde, China.
  6. Jiaozi Che: Clinical lab, Chengde central Hospital, Chengde, China.

Abstract

BACKGROUND: exanthematous drug eruption and infectious mononucleosis (IM) are both exanthematous diseases. Current research on exanthematous drug eruption and IM mainly targets identifying these disorders, the resulting differences at the metabolism level have not yet been systematically analyzed.
MATERIALS AND METHODS: A total of 30 cases of exanthematous drug eruption and IM, 10 patients without exanthema and 10 healthy volunteers were enrolled, 3 mL of fasting venous blood was collected, the serum metabolite content was detected by gas chromatography-mass spectrometry metabolomics.
RESULTS: A total of 165 metabolites were identified, exhibiting significant differences in plasma metabolic trends between exanthematous drug eruption and IM, and pinpointed 28 potential biomarkers. Notable changes were seen in the metabolic activities of the pentose phosphate pathway (PPP), tricarboxylic acid cycle (TCA-cycle), and galactose metabolism, characterized by increased levels of gluconate, gluconolactone, glucose, galactaric acid, and mannose, along with decreased amounts of pyruvic acid, succinic acid, malic acid, and glycerol, indicating an impairment in the exanthematous drug eruption group's capacity to endure oxidative stress and regulate energy metabolism. In contrast to its medication without rash counterpart, the exanthematous drug eruption group's plasma displayed distinct metabolic routes, predominantly in the processing of arginine and proline, along with the TCA. This resulted in a marked reduction in urea levels and a rise in pyruvate, citrate, and ornithine, indicating hypoxic stress as the primary cause of these rashes. In contrast to the healthy control group, the IM group showed 26 potential biomarkers, marked by increased levels of ketoglutaric acid, malic acid, pyruvic acid, and oxoglutaric acid, and reduced amounts of glutamine, galacturonic acid, arachidonic acid, trimethylphosphonic acid ester, gluconolactone, and indole acetic acid. Mainly, the metabolic pathways included the TCA, breaking down alanine, aspartate and glutamate metabolism, and the processing of D-glutamine and D-glutamate metabolism, underscoring the body's crucial role in generating energy and inflammatory agents through the citric acid cycle.
CONCLUSIONS: The comparison of serum metabolomic features of exanthematous drug eruptions and IM outlines a unique pattern closely related to the differences in the pathogenesis of these two exanthematous diseases.

Keywords

References

  1. Cells. 2021 Jun 08;10(6): [PMID: 34201149]
  2. Microvasc Res. 2003 Sep;66(2):91-101 [PMID: 12935767]
  3. Viruses. 2023 Feb 13;15(2): [PMID: 36851739]
  4. Biochem J. 1998 Nov 15;336 ( Pt 1):1-17 [PMID: 9806879]
  5. Curr Opin Clin Nutr Metab Care. 2015 Jul;18(4):422-7 [PMID: 26001656]
  6. World Neurosurg. 2021 Nov;155:1-12 [PMID: 34365049]
  7. Biochim Biophys Acta Rev Cancer. 2023 Nov;1878(6):188970 [PMID: 37657682]
  8. Trends Genet. 1998 Mar;14(3):98-102 [PMID: 9540406]
  9. Mol Ther. 2023 Jan 4;31(1):269-281 [PMID: 36114672]
  10. ESC Heart Fail. 2021 Jun;8(3):1738-1750 [PMID: 33783981]
  11. Cell Metab. 2017 Aug 1;26(2):281-283 [PMID: 28768165]
  12. Biochim Biophys Acta Gen Subj. 2021 Aug;1865(8):129898 [PMID: 33878388]
  13. J Neuroimmunol. 2022 Jan 15;362:577778 [PMID: 34814011]
  14. J R Coll Gen Pract. 1969 Jun;17(83):340-50 [PMID: 5786469]
  15. Skin Res Technol. 2024 Oct;30(10):e70043 [PMID: 39387831]
  16. Cell Metab. 2019 Sep 3;30(3):539-555.e11 [PMID: 31257153]
  17. J Med Food. 2014 May;17(5):588-98 [PMID: 24433072]
  18. ChemMedChem. 2018 Apr 23;13(8):764-778 [PMID: 29441721]
  19. Int J Mol Sci. 2022 Aug 07;23(15): [PMID: 35955911]
  20. Allergy. 2021 Apr;76(4):1199-1212 [PMID: 32813887]
  21. Diab Vasc Dis Res. 2012 Jan;9(1):42-51 [PMID: 22045866]
  22. Int J Cardiol. 2022 Jan 1;346:86-92 [PMID: 34800594]
  23. Life Sci. 2021 Dec 1;286:120040 [PMID: 34637794]
  24. J Allergy Clin Immunol Glob. 2023 Aug;2(3): [PMID: 37609569]
  25. Br J Dermatol. 1997 Dec;137(6):934-8 [PMID: 9470910]
  26. Int J Mol Sci. 2019 May 18;20(10): [PMID: 31109071]
  27. Mol Ther. 2022 Apr 6;30(4):1523-1535 [PMID: 35077861]
  28. Cell Rep. 2018 Sep 18;24(12):3087-3098 [PMID: 30231992]
  29. Curr Opin Infect Dis. 2009 Jun;22(3):272-8 [PMID: 19398898]
  30. Clin J Am Soc Nephrol. 2020 Mar 6;15(3):404-411 [PMID: 31636087]
  31. Elife. 2021 Dec 23;10: [PMID: 34939929]
  32. Cells. 2021 Oct 21;10(11): [PMID: 34831057]
  33. EBioMedicine. 2021 Nov;73:103672 [PMID: 34740102]
  34. J Clin Pathol Suppl (R Coll Pathol). 1972;6:58-64 [PMID: 4376156]
  35. J Biochem Mol Biol. 2004 Mar 31;37(2):239-45 [PMID: 15469702]
  36. Reprod Fertil. 2021 May 06;2(2):R35-R50 [PMID: 35128453]
  37. Allergy. 2017 Sep;72(9):1327-1337 [PMID: 28213886]
  38. Nature. 2014 Jul 10;511(7508):167-76 [PMID: 25008522]
  39. Nutr Rev. 1995 Jul;53(7):186-93 [PMID: 7494620]

Grants

  1. 21377714D/Hebei Provincial Department of Science and Technology

MeSH Term

Humans
Drug Eruptions
Male
Female
Adult
Metabolomics
Infectious Mononucleosis
Biomarkers
Exanthema
Young Adult
Middle Aged
Adolescent
Metabolome
Citric Acid Cycle
Gas Chromatography-Mass Spectrometry
Pentose Phosphate Pathway

Chemicals

Biomarkers

Word Cloud

Created with Highcharts 10.0.0acidexanthematousdrugeruptionIMmetabolismdifferencesmetabolicinfectiousmononucleosislevelsdiseasestotal10withouthealthyserumplasmapotentialbiomarkerscycleincreasedgluconolactonealongamountspyruvicmalicindicatinggroup'sstressenergycontrastprocessingTCAmarkedgroupmetabolomicpathogenesisBACKGROUND:ExanthematousCurrentresearchmainlytargetsidentifyingdisordersresultinglevelyetsystematicallyanalyzedMATERIALSANDMETHODS:30casespatientsexanthemavolunteersenrolled3 mLfastingvenousbloodcollectedmetabolitecontentdetectedgaschromatography-massspectrometrymetabolomicsRESULTS:165metabolitesidentifiedexhibitingsignificanttrendspinpointed28NotablechangesseenactivitiespentosephosphatepathwayPPPtricarboxylicTCA-cyclegalactosecharacterizedgluconateglucosegalactaricmannosedecreasedsuccinicglycerolimpairmentcapacityendureoxidativeregulatemedicationrashcounterpartdisplayeddistinctroutespredominantlyarginineprolineresultedreductionurearisepyruvatecitrateornithinehypoxicprimarycauserashescontrolshowed26ketoglutaricoxoglutaricreducedglutaminegalacturonicarachidonictrimethylphosphonicesterindoleaceticMainlypathwaysincludedbreakingalanineaspartateglutamateD-glutamineD-glutamateunderscoringbody'scrucialrolegeneratinginflammatoryagentscitricCONCLUSIONS:comparisonfeatureseruptionsoutlinesuniquepatterncloselyrelatedtwoMetabolomic

Similar Articles

Cited By (1)